From providing medically reviewed expert content on the basics to the latest news and research on Non-Small-Cell Lung Cancer, Everyday Health has got you covered.
Angle Plc - Announces Parsortix: Dynamic Assessment of Patient Response theusnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theusnews.com Daily Mail and Mail on Sunday newspapers.
ANGLE plc: Angle Plc - Announces Parsortix: Dynamic Assessment of Patient Response
Use of Parsortix System Enables a Dynamic Assessment of Patient Response to Treatment in Non-Small Cell Lung Cancer
CTCs harvested by the Parsortix system successfully used to measure the dynamic role of EMT and PD-L1 in patient response to therapy
Findings support ANGLE s plan for the growth of a new pharma services business area using the Parsortix system as a biomarker for cancer drug trials allowing longitudinal monitoring of patients
GUILDFORD, SURREY / ACCESSWIRE / February 8, 2021 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company, is pleased to announce that the National and Kapodistrian University of Athens (Athens) has published results of a new study undertaken in non-small cell lung cancer (NSCLC). This study demonstrates the utility of ANGLE s Parsortix
Biomarkers could help discriminate cancer therapy-associated kidney injury from other causes
A study by Mayo Clinic researchers published in
Kidney International Reports finds that immune checkpoint inhibitors, may have negative consequences in some patients, including acute kidney inflammation, known as interstitial nephritis. Immune checkpoint inhibitors are used to treat cancer by stimulating the immune system to attack cancerous cells.
Immune checkpoint inhibitors have improved the prognosis for patients with a wide range of malignancies including melanoma, non-small cell lung cancer and renal cancer. In some patients, this enhanced immune response may target kidney tissue, leading to acute kidney inflammation known as interstitial nephritis.
Report proffers a comprehensive outlay of the Smoking Cessation Epidemiological analysis focusing on the incidence and diagnosed patient pool segmented on the basis of several factors, as well as the upcoming trends of the Smoking Cessation epidemiology that is going to impact the overall patient pool and the market outlook in the 7MM (the US, EU5 (the UK, France, Germany, Italy and Spain) and Japan).
The report covers the Smoking Cessation market trends covering key pharmaceutical companies in the market, upcoming as well as Smoking Cessation marketed therapies, unmet needs, prevailing constraints and the factors driving the market size growth.